Under the C-diff section on Immuron’s website it says- “Results for Immuron’s animal recurrence studies will be available this January. Positive results in the study would conclude that IMM-529 would be beneficial in treatments for all three phases of the disease, prevention, initial treatment, and recurrence, with recurrence being the largest unmet need
“
Anyone heard anything about the results because it is already February?
C-diff results.
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.001(1.01%) |
Mkt cap ! $22.8M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.0¢ | 9.9¢ | $21.40K | 214.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10653 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 207757 | 9 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.001 ( 1.01 %) |
||||
| Open | High | Low | Volume | ||
| 10.0¢ | 10.0¢ | 9.9¢ | 53043 | ||
| Last updated 12.15pm 03/05/2024 ? | |||||
| IMC (ASX) Chart |